Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EASi-PROTKT study of vicadrostat added to empagliflozin in adults with type 2 diabetes, hypertension, and established cardiovascular disease
2025-521188-11-00Phase 3Authorised
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 50
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM), hypertension (HTN) and cardiac morbidity comparing Vicadrostat + empagliflozin with Placebo + empagliflozin (2 arms). Primary endpoint: Time to first event of cardiovascular death or heart failure event. Planned start Oct 2025; status: authorised.
02
Drugs
vicadrostatempagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)hypertension (HTN)cardiac morbidity
Beyond the preview
Go deeper on 2025-521188-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521188-11-00.